From coronary stents to defibrillators, and from pacemakers to devices that mask chronic pain, Boston Scientific aims to build the best possible medical solutions to support physicians and their patients. The company currently offers more than 13,000 products across 100-plus countries—and it's perpetually growing that portfolio by investing in both innovation and mergers and acquisitions (M&A). To support those ongoing research and development (R&D) and M&A investments, the treasury team is perpetually looking for ways to "fund the journey to fuel growth," as the company's strategy statement puts it.
Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.
Your access to unlimited Treasury & Risk content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Thought leadership on regulatory changes, economic trends, corporate success stories, and tactical solutions for treasurers, CFOs, risk managers, controllers, and other finance professionals
- Informative weekly newsletter featuring news, analysis, real-world case studies, and other critical content
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Meg Waters
Meg Waters is the editor in chief of Treasury & Risk. She is the former editor in chief of BPM Magazine and the former managing editor of Business Finance.
